BioScrip Inc (NASDAQ:BIOS) shares rose 7.3% during trading on Wednesday . The stock traded as high as $3.12 and last traded at $3.07, approximately 2,283,400 shares traded hands during trading. An increase of 104% from the average daily volume of 1,119,774 shares. The stock had previously closed at $2.86.
BIOS has been the topic of several research reports. ValuEngine upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Monday, November 11th. BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Saturday, November 9th. SunTrust Banks lifted their price target on BioScrip from $3.25 to $4.25 and gave the company a “buy” rating in a report on Friday, September 20th. Canaccord Genuity lifted their price target on BioScrip from $3.50 to $4.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating and set a $4.00 price target on the stock. in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $4.79.
The stock has a fifty day moving average price of $3.42 and a 200-day moving average price of $2.98. The firm has a market capitalization of $2.17 billion, a PE ratio of -6.27 and a beta of 0.44. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.36 and a current ratio of 1.71.
Large investors have recently made changes to their positions in the company. Wells Fargo & Company MN increased its holdings in shares of BioScrip by 121.4% in the 2nd quarter. Wells Fargo & Company MN now owns 761,957 shares of the company’s stock valued at $1,981,000 after acquiring an additional 417,806 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of BioScrip in the 2nd quarter valued at $2,275,000. Venor Capital Management LP grew its stake in BioScrip by 3.4% during the 2nd quarter. Venor Capital Management LP now owns 12,333,605 shares of the company’s stock worth $32,067,000 after buying an additional 400,000 shares during the last quarter. Citadel Advisors LLC purchased a new position in BioScrip during the 2nd quarter worth $125,000. Finally, SG Americas Securities LLC purchased a new position in BioScrip during the 3rd quarter worth $63,000. Institutional investors and hedge funds own 15.49% of the company’s stock.
BioScrip Company Profile (NASDAQ:BIOS)
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
Recommended Story: Cash Flow Analysis in Stock Selection
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.